Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...

Cartesian Therapeutics updates on Descartes-08 trials in myasthenia gravis and lupus, with financial results highlighting $182.1 million in cash. Cartesian Therapeutics, Inc. has announced the ...

NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation III (the “Company”) announced today the pricing of its initial public offering of 24,000,000 units, upsized from 20,000,000 units, at a price of ...

Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25 Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol Assessment ...

Moving an object from one location to another—picking and placing—is an ideal application for industrial robots due to the robots’ repeatability, throughput and favorable return on investment. It is ...

Cartesian Therapeutics has claimed a phase 2b win for its BCMA-directed CAR-T therapy in generalized myasthenia gravis (gMG). But the biotech’s victory came on a primary endpoint it changed in May and ...

Astellas is putting the kibosh on a licensing deal with Cartesian Therapeutics, deciding it’s no longer interested in using the latter’s Xork asset to help treat Pompe disease. The decision disclosed ...

GAITHERSBURG, Md., March 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today ...

The Cartesian Coordinate is a Fusion Rifle that originally launched back in Season of the Chosen. While it popped off thanks to the Particle Deconstruction perk in the Season of the Lost Artifact, a ...